-
Selinexor trans-isomer
- names:
O=C(NNC1=NC=CN=C1)/C=C/N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
- CAS号:
1421923-86-5
MDL Number: - MF(分子式): C17H11F6N7O MW(分子量): 443.31
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | O=C(NNC1=NC=CN=C1)/C=C/N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2 |
| 英文别名 | KPT-330 E-isomer; KPT330 trans isomer; E-KPT 330; Selinexor E-isomer; Selinexor trans-isomer |
| CAS号 | 1421923-86-5 |
| Inchi | InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1+ |
| InchiKey | DEVSOMFAQLZNKR-DAFODLJHSA-N |
| 分子式 Formula | C17H11F6N7O |
| 分子量 Molecular Weight | 443.31 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Selinexor trans-isomer(CAS:1421923-86-5 ):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Selinexor trans-isomer is a trans-isomer of Selinexor or KPT-330, which is a CRM1-selective inhibitor of nuclear export. It inhibits protein trafficking from the nucleus and induces cell cycle arrest and apoptosis in mesothelioma cells. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Ben-Barouch S, Kuruvilla J. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs. 2019 Dec 17. doi: 10.1080/13543784.2020.1706087. [Epub ahead of print] PubMed PMID: 31847605. |
| [2]Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al Hallak MN, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA. Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019 Dec 12. pii: clincanres.1728.2019. doi: 10.1158/1078-0432.CCR-19-1728. [Epub ahead of print] PubMed PMID: 31831564. |
| [3] Vergote IB, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, Van Nieuwenhuysen E, Haslund C, Nottrup T, Han SN, Concin N, Unger TJ, Chai Y, Au N, Rashal T, Joshi A, Crochiere M, Landesman Y, Shah J, Shacham S, Kauffman M, Mirza MR. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol. 2019 Dec 7. pii: S0090-8258(19)31663-4. doi: 10.1016/j.ygyno.2019.11.012. [Epub ahead of print] PubMed PMID: 31822399. |
| [4] Peterson TJ, Orozco J, Buege M. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma. Ann Pharmacother. 2019 Dec |
| [5]1060028019892643. doi: 10.1177/1060028019892643. [Epub ahead of print] PubMed PMID: 31793336. |
5: Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2019 Nov 21. pii: haematol.2019.236810. doi: 10.3324/haematol.2019.236810. [Epub ahead of print] PubMed PMID: 31753931.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


